Verzenio (Abemaciclib) – Breast Cancer | HongKong DengYue Medicine
- Generic Name/Brand Name: Abemaciclib/Verzenio
- Indications: HR-positive / HER2-negative advanced/ metastatic breast cancer
- Dosage Form: Oral tablets
- Specification: 50 mg/100 mg/150 mg/200 mg × 14 tablets
Verzenio Application Scope
Verzenio (abemaciclib) is a prescription medicine used to treat Hormone Receptor (HR)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer in specific situations.

Verzenio Characteristics
Ingredients: Abemaciclib
Properties: A selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6)
Packaging Specification: Tablets available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg
Storage: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)
Expiry Date: Refer to the expiry date printed on the packaging
Executive Standard: Complies with FDA regulations for oncology medications
Approval Number: NDA 208716
Date of Revision: October 2021
Manufacturer: Eli Lilly and Company
Guidelines for the Use of Verzenio
Dosage and Administration:
Recommended Dose:
In combination with endocrine therapy (tamoxifen or an aromatase inhibitor): 150 mg orally twice daily.
In combination with fulvestrant: 150 mg orally twice daily.
As monotherapy: 200 mg orally twice daily.
Administration:
May be taken with or without food.
Swallow tablets whole; do not chew, crush, or split.
If a dose is missed, take the next dose at the scheduled time; do not take two doses at once.
Missed Dose:
If a dose is missed, take the next dose at the scheduled time.
Do not take two doses at once to make up for a missed dose.
Adverse Reactions:
Common Adverse Reactions:
Diarrhea
Neutropenia
Fatigue
Anemia
Nausea
Leukopenia
Headache
Serious Adverse Reactions:
Infections
Pneumonitis
Cardiac events (e.g., heart failure)
Gastrointestinal perforation
Contraindications:
Pregnancy: Verzenio can cause harm to a developing fetus. It is not recommended for use during pregnancy. Effective contraception is required during treatment and for at least 3 weeks after the last dose.
Breastfeeding: It is not recommended to breastfeed while taking Verzenio and for at least 3 weeks after the final dose, as it is not known if the drug passes into breast milk.
Precautions:
Your doctor will monitor your blood cell counts and liver function before and during treatment.
Report any signs of infection (e.g., fever, chills) or diarrhea to your doctor immediately.
Inform your doctor of all other medications you are taking, including over-the-counter drugs and herbal supplements, due to potential interactions.
Verzenio Interactions
Drug Interactions:
Strong CYP3A inhibitors (e.g., ketoconazole) may increase abemaciclib plasma concentrations.
Strong CYP3A inducers (e.g., rifampin) may decrease abemaciclib plasma concentrations.
Avoid co-administration with strong CYP3A inhibitors or inducers.
Food Interactions:
No significant food interactions identified.
Note:
- If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
- This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.










Reviews
There are no reviews yet.